Paul Myers, MD
Cardiovascular Disease · Nashville, TNNPI 1245325661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,611, 5.5 times the $292 reported in 2019.
Across 333 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$777
- Novo Nordisk$759
- Amgen$720
- Boehringer Ingelheim$513
- Merck$460
- Pfizer$390
- plus $2K from 28 others
Across 77 payments — averaging $6278.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$330K
- Medtronic$103K
- Abbott$17K
- CSL Behring$12K
- Boehringer Ingelheim International GmbH$12K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
What the payments were for
- Food & beverage$5,69498%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 51 | $777 |
| Novo Nordisk | 40 | $759 |
| Amgen(2 entities) | 47 | $720 |
| Boehringer Ingelheim | 33 | $513 |
| Merck | 23 | $460 |
| Pfizer | 22 | $390 |
| AstraZeneca | 20 | $341 |
| Boston Scientific | 9 | $316 |
| Sanofi-aventis U.S. LLC | 13 | $234 |
| Philips North America LLC | 16 | $232 |
| Lexicon Pharmaceuticals, Inc. | 6 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $97 |
| Bayer | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Amarin Pharma, Inc. | 5 | $71 |
| Johnson & Johnson | 4 | $66 |
| Vital Connect, Inc | 2 | $60 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Bridgebio Pharma, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 3 | $43 |
| Scpharmaceuticals Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| GSK | 2 | $33 |
| Heartflow, Inc. | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,791 in reported general payments places this provider in the 70th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 645 | $585,313 |
| EliquisApixaban | 461 | $380,729 |
| EntrestoSacubitril/Valsartan | 195 | $191,477 |
| Praluent PenAlirocumab | 121 | $145,178 |
| XareltoRivaroxaban | 142 | $131,892 |
| JardianceEmpagliflozin | 178 | $128,189 |
| FarxigaDapagliflozin Propanediol | 136 | $89,852 |
| MultaqDronedarone Hcl | 59 | $49,452 |
| VascepaIcosapent Ethyl | 69 | $44,912 |
| NexletolBempedoic Acid | 62 | $41,794 |
| Repatha SyringeEvolocumab | 61 | $39,910 |
| OzempicSemaglutide | 30 | $30,296 |
| Repatha PushtronexEvolocumab | 15 | $19,027 |
| Ranolazine ErRanolazine | 89 | $16,974 |
| Icosapent Ethyl | 39 | $14,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $390 | $380,729461 claims |
| NovartisEntresto | $777 | $191,477195 claims |
| Johnson & JohnsonXarelto | $66 | $131,892142 claims |
| Boehringer IngelheimJardiance | $513 | $128,189178 claims |
| AstraZenecaFarxiga | $341 | $89,852136 claims |
| Sanofi-aventis U.S. LLCMultaq | $234 | $49,45259 claims |
| Esperion Therapeutics, Inc.Nexletol | $34 | $41,79462 claims |
| Novo NordiskOzempic | $759 | $30,29630 claims |
| AmgenCorlanor | $720 | $13,47119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.